Abstract
Purpose
Dexamethasone has a high therapeutic index when used to prevent chemotherapy-induced nausea and vomiting. However, the chronic use of glucocorticoids has been associated with suppression of the hypothalamic–pituitary–adrenal axis. Therefore, the authors designed this pilot study to assess the incidence of adrenal insufficiency after dexamethasone therapy as an antiemetic in cancer patients receiving chemotherapy.
Methods
The rapid adrenocorticotropic hormone (ACTH) stimulation test was performed in 103 cancer patients, who had been treated with high-dose dexamethasone as an antiemetic for more than 3 months. When response to the rapid ACTH stimulation test was abnormal, the patient received corticosteroid replacement by prednisolone 7.5 mg daily for 1–2 weeks and after prednisolone replacement, changes in symptoms associated with adrenal insufficiency were investigated using a visual analog scale.
Results
Forty-five of the 103 patients (43.7%) showed a suppressed adrenal response to the rapid ACTH stimulation test, and the incidence of adrenal suppression was found to be significantly affected by megestrol acetate use (P = 0.035). Thirty-three patients with a suppressed adrenal function achieved an improvement in quality of life after prednisolone replacement, as determined using a self-report questionnaire (22.9 ± 14.7 to 14.8 ± 11.0, P < 0.001).
Conclusions
We suggest that suppression of adrenal response is common after antiemetic dexamethasone therapy in cancer patients receiving chemotherapy.
Similar content being viewed by others
References
Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MH (1996) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189–195
Laszlo J, Lucas VS Jr (1981) Emesis as a critical problem in chemotherapy. N Engl J Med 305:948–949
Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95:155–163
American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932–2947
Roila F, Tonato M, Basurto C, Picciafuoco M, Bracarda S, Donati D, Malacarne P, Monici L, Di Costanzo F, Patoia L et al (1989) Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J Clin Oncol 7:1693–1700
Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C (1997) Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15:2966–2973
Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocol 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112–4119
Arlt W, Allolio B (2003) Adrenal insufficiency. Lancet 361:1881–1893
Oelkers W (1996) Adrenal insufficiency. N Engl J Med 335:1206–1212
Seravalli L (2009) Predisposing factors for adrenal insufficiency. N Engl J Med 361:824–825
Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J (2008) Harrison's principles of internal medicine, 17th edn. McGraw-Hill, New York, pp 2262–2266
Tordjman K, Jaffe A, Trostanetsky Y, Greenman Y, Limor R, Stern N (2000) Low-dose (1 microgram) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test. Clin Endocrinol 52:633–640
Byyny RL (1976) Withdrawal from glucocorticoid therapy. N Engl J Med 295:30–32
Myles AB, Schiller LF, Glass D, Daly JR (1976) Single daily dose corticosteroid treatment. Ann Rheum Dis 35:73–76
Schlaghecke R, Kornely E, Santen RT, Ridderskamp P (1992) The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 326:226–230
Christy NP (1992) Pituitary-adrenal function during corticosteroid therapy. Learning to live with uncertainty. N Engl J Med 326:266–267
Spiegel RJ, Vigersky RA, Oliff AI, Echelberger CK, Bruton J, Poplack DG (1979) Adrenal suppression after short-term corticosteroid therapy. Lancet 1:630–633
Carella MJ, Srivastava LS, Gossain VV, Rovner DR (1993) Hypothalamic-pituitary-adrenal function one week after a short burst of steroid therapy. J Clin Endocrinol Metab 76:1188–1191
Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA (2000) Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 355:542–545
Schmoll E, Wilke H, Thole R, Preusser P, Wildfang I, Schmoll HJ (1991) Megestrol acetate in cancer cachexia. Semin Oncol 18:32–34
Loprinzi CL (1995) Management of cancer anorexia/cachexia. Support Care Cancer 3:120–122
Tchekmedyian NS, Hickman M, Siau J, Greco FA, Keller J, Browder H, Aisner J (1992) Megestrol acetate in cancer anorexia and weight loss. Cancer 69:1268–1274
Naing KK, Dewar JA, Leese GP (1999) Megestrol acetate therapy and secondary adrenal suppression. Cancer 86:1044–1049
Ron IG, Soyfer V, Goldray D, Inbar MJ, Weisman Y (2002) A low-dose adrenocorticotropin test reveals impaired adrenal function in cancer patients receiving megestrol acetate therapy. Eur J Cancer 38:1490–1494
Orme LM, Bond JD, Humphrey MS, Zacharin MR, Downie PA, Jamsen KM, Mitchell SL, Robinson JM, Grapsas NA, Ashley DM (2003) Megestrol acetate in pediatric oncology patients may lead to severe, symptomatic adrenal suppression. Cancer 98:397–405
Loprinzi CL, Jensen MD, Jiang NS, Schaid DJ (1992) Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clinic Proc 67:1160–1162
Lamberts SW, Bruining HA, de Jong FH (1997) Corticosteroid therapy in severe illness. N Engl J Med 337:1285–1292
Morrow GR, Hickok JT, Andrews PL, Stern RM (2002) Reduction in serum cortisol after platinum based chemotherapy for cancer: a role for the HPA axis in treatment-related nausea? Psychophysiology 39:491–495
Acknowledgments
This work was supported by the research grant of the Chungbuk National University in 2010.
Conflict of interest
We declare that no conflict of interest exists for any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
Hye-Suk Han and Young Kwang Shim contributed equally as first authors to this work.
Appendix A
Appendix A
A self-report questionnaire composed of six most common symptoms associated with adrenal insufficiency
Rights and permissions
About this article
Cite this article
Han, HS., Shim, Y.K., Kim, J.E. et al. A pilot study of adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients. Support Care Cancer 20, 1565–1572 (2012). https://doi.org/10.1007/s00520-011-1248-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-011-1248-z